Literature DB >> 31121562

METTL7B promotes migration and invasion in thyroid cancer through epithelial-mesenchymal transition.

Danrong Ye1, Yang Jiang1, Yihan Sun1, Yuefeng Li1, Yefeng Cai1, Qingxuan Wang1, Ouchen Wang1, Endong Chen1, Xiaohua Zhang1.   

Abstract

Thyroid cancer is associated with one of the most malignant endocrine tumors. However, molecular mechanisms underlying thyroid tumorigenesis and progression remain unclear. In order to investigate these mechanisms, we performed whole-transcriptome sequencing, which indicated that a differentially expressed gene, METTL7B, was highly expressed in thyroid cancers. We analyzed METTL7B expression using TCGA and performed qRT-PCR on tissue samples. Moreover, an analysis of clinicopathological characteristics revealed a positive correlation between METTL7B and lymph node metastasis. A series of in vitro experiments indicated that METTL7B enhanced migration and invasion of thyroid carcinoma cells. Further studies revealed that METTL7B may enhance TGF-β1-induced epithelial-mesenchymal transition (EMT). Our results indicate that METTL7B may promote metastasis of thyroid cancer through EMT and may therefore be considered as a potential biomarker for the diagnosis and prognosis of thyroid carcinoma.

Entities:  

Keywords:  METTL7B; epithelial-mesenchymal transition; metastasis; thyroid cancer

Year:  2019        PMID: 31121562     DOI: 10.1530/JME-18-0261

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  9 in total

Review 1.  METTLing in Stem Cell and Cancer Biology.

Authors:  John G Tooley; James P Catlin; Christine E Schaner Tooley
Journal:  Stem Cell Rev Rep       Date:  2022-09-12       Impact factor: 6.692

2.  Methyltransferase like 7B is upregulated in sepsis and modulates lipopolysaccharide-induced inflammatory response and macrophage polarization.

Authors:  Dan Huang; Hai Yan
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  Identification of the EMT-Related Genes Signature for Predicting Occurrence and Progression in Thyroid Cancer.

Authors:  Qiang Li; Sheng Jiang; Tienan Feng; Tengteng Zhu; Biyun Qian
Journal:  Onco Targets Ther       Date:  2021-05-12       Impact factor: 4.147

4.  Downregulation of METTL7B Inhibits Proliferation of Human Clear Cell Renal Cancer Cells In Vivo and In Vitro.

Authors:  Wei Li; Shi Xu; Naixiong Peng; Zejian Zhang; Hua He; Ruoyu Chen; Dong Chen; Jiqing Fan; Xisheng Wang
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

5.  METTL7B (methyltransferase-like 7B) identification as a novel biomarker for lung adenocarcinoma.

Authors:  Jawad Ali; Wenwen Liu; Wenzhe Duan; Chang Liu; Jing Song; Sameen Ali; Encheng Li; Qi Wang
Journal:  Ann Transl Med       Date:  2020-09

6.  Human METTL7B is an alkyl thiol methyltransferase that metabolizes hydrogen sulfide and captopril.

Authors:  Benjamin J Maldonato; Drake A Russell; Rheem A Totah
Journal:  Sci Rep       Date:  2021-03-01       Impact factor: 4.379

7.  Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma.

Authors:  Huibin Song; Dongcheng Liu; Lingwei Wang; Kaisheng Liu; Chen Chen; Le Wang; Yi Ren; Bing Ju; Fuhua Zhong; Xingyu Jiang; Guangsuo Wang; Zhe-Sheng Chen; Chang Zou
Journal:  Mol Cancer       Date:  2022-02-10       Impact factor: 27.401

8.  METTL7B is a novel prognostic biomarker of lower-grade glioma based on pan-cancer analysis.

Authors:  Zhipeng Jiang; Wen Yin; Hecheng Zhu; Jun Tan; Youwei Guo; Zhaoqi Xin; Quanwei Zhou; Yudong Cao; Zhaoping Wu; Yirui Kuang; Can Li; Dongcheng Xie; Hailong Huang; Ming Zhao; Xingjun Jiang; Lei Wang; Caiping Ren
Journal:  Cancer Cell Int       Date:  2021-07-19       Impact factor: 5.722

9.  Establishment and Validation of a Comprehensive Prognostic Model for Patients With HNSCC Metastasis.

Authors:  Yajun Shen; Lingyu Li; Yunping Lu; Min Zhang; Xin Huang; Xiaofei Tang
Journal:  Front Genet       Date:  2021-07-12       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.